Comparative Pharmacology
Head-to-head clinical analysis: DISOPHROL versus PROMETH FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPHROL versus PROMETH FORTIS.
DISOPHROL vs PROMETH FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine